I tend to agree given the somewhat unique territory NEU is working in. Also, there are plenty of commercialised drugs out there worth a lot of money that have average efficacy, but average is considered better than nothing in their cases.
So I think NEU stands in a good position compared to many biotechs tackling competitive areas such as oncology etc. However, if good but not great results occur, I don't think it will put a fire under the SP until any concrete talk of pharma deals eventuate.
I tend to agree given the somewhat unique territory NEU is...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.73 |
Change
0.430(2.23%) |
Mkt cap ! $2.516B | |||
| Open | High | Low | Value | Volume |
| $19.80 | $20.00 | $19.40 | $1.917M | 97.40K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 8 | $19.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.73 | 126 | 7 |
View Market Depth
| Last trade - 13.56pm 11/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |